Cahaba Wealth Management Inc. Has $1.06 Million Holdings in Johnson & Johnson $JNJ

Cahaba Wealth Management Inc. grew its stake in Johnson & Johnson (NYSE:JNJ) by 28.2% during the 2nd quarter, HoldingsChannel reports. The firm owned 6,931 shares of the company’s stock after acquiring an additional 1,523 shares during the quarter. Cahaba Wealth Management Inc.’s holdings in Johnson & Johnson were worth $1,059,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Highline Wealth Partners LLC grew its holdings in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new position in Johnson & Johnson in the 1st quarter valued at approximately $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson in the first quarter worth $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson during the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 1.1%

NYSE JNJ opened at $179.69 on Friday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock’s 50-day simple moving average is $174.41 and its two-hundred day simple moving average is $162.06. The company has a market capitalization of $432.75 billion, a price-to-earnings ratio of 19.22, a PEG ratio of 2.29 and a beta of 0.40. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Bank of America upped their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. The Goldman Sachs Group increased their target price on Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $181.40.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.